Industry Overview - The vaccine industry is experiencing a structural opportunity due to the rising trend of influenza, with a focus on flu vaccine developments [2][4] - Recent approvals for clinical trials include various vaccines from companies like Zhifei Biological, including a pertussis-diphtheria-tetanus vaccine and an mRNA shingles vaccine [2][4] - The National Influenza Center reported an increase in flu activity, with a total of 621 reported influenza-like illness outbreaks across the country [4] Market Performance - The vaccine sector saw a 3% increase, with the overall pharmaceutical and biological sector rising by 3.29% during the week of November 9-15, 2025 [5] - Notable companies in the vaccine sector that performed well include Jindike, Hualan Biological, and Baike Biological, while companies like Wantai Biological and Zhifei Biological lagged [6] Valuation Metrics - The vaccine sector's price-to-earnings (PE) ratio (ttm) was 101.87X, reflecting a 2.8X increase week-over-week, while the price-to-book (PB) ratio was 1.99X, up by 0.05X [7][8] Investment Insights - The vaccine industry is under pressure, with a notable structural differentiation among companies. The focus is on innovation and international expansion as key strategies for long-term growth [9] - The industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition causing short-term challenges [9] - Key drivers for the industry's long-term growth include policy support, demand increase due to an aging population, and technological advancements [10] Recommendations - Companies with strong research and development capabilities and differentiated product offerings, such as CanSino and Kanghua Biological, are recommended for investment [10] - Short-term focus should be on companies involved in flu vaccines due to the seasonal increase in demand [10]

1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更前次股东会决议的情形。 一、会议召开和出席情况 证券代码：002007 证券简称：华兰生物 公告编号：2025-045 华兰生物工程股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会的召开时间： 现场会议召开时间为：2025年11月17日14:30 网络投票时间：2025年11月17日。其中通过深圳证券交易所交易系统进行网络 投票的具体时间为2025年11月17日上午9:15—9:25,9:30—11:30和下午13:00— 15:00；通过深圳证券交易所互联网投票的具体时间为2025年11月17日09:15至15:00 期间的任意时间。 2、会议召开地点：公司办公楼会议室 3、会议方式：现场投票、网络投票相结合的方式 4、召集人：公司董事会 5、现场会议主持人：董事长安康先生 6、本次股东会的会议召集、召开程序符合有关法律、法规、规范性文件及《公 司章程》的有关规定。 7、会议出席情况： （1）出席会议总体情况 出席本次股东 ...

安徽承义律师事务所 关于 华兰生物工程股份有限公司 召开 2025 年第三次临时股东会的 法律意见书 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物工程股份有限公司 召开 2025 年第三次临时股东会的法律意见书 （2025）承义法字第 00247 号 致：华兰生物工程股份有限公司 经核查，本次股东会审议的提案为《关于补选第九届董事会独立董事的议案》 《关于授权关联方使用公司注册商标暨关联交易的议案》，上述提案由公司第九 届董事会提出，上述提案与会议通知一并进行了公告。本次股东会没有临时提案。 本次股东会的提案人资格及提案提出的程序均符合法律、法规、规范性文件 和公司章程的规定。 四、本次股东会的表决程序和表决结果 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等 ...

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-11-17 | 002007 | 华兰生物 | 16.42 | 150.00 | 2,463.〔机构专用 | | 中国国际金融股份 | | | | | | | | | 有限公司上海分公 ם | 11月17日，华兰生物大宗交易成交150万股，成交额2463万元，占当日总成交额的5.1%，成交价16.42 元，较市场收盘价16.42元持平。 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Viewpoints - The report highlights a rising trend in influenza activity, suggesting a structural opportunity in the flu vaccine market. It emphasizes the importance of focusing on innovative vaccines and companies with differentiated pipelines to capture alpha opportunities in a competitive landscape [8][9][27]. Summary by Relevant Sections Industry Performance - Over the past twelve months, the vaccine sector has shown a relative performance of -25% compared to the CSI 300 index, with an absolute return of -5% [3][4]. - The vaccine sector's PE (ttm) is reported at 101.87X, with a PB (lf) of 1.99X, indicating a slight increase in valuation metrics [7][20]. Domestic and International Vaccine Dynamics - Recent approvals for clinical trials include various vaccines from companies like Zhifei Biological Products and CanSino, indicating ongoing innovation in the sector [4][8]. - The National Influenza Center reported an increase in flu cases, with 621 outbreaks reported, suggesting a potential uptick in demand for flu vaccines [4][8]. Market Review - The vaccine sector experienced a 3% increase in the last week, reflecting a moderate performance compared to other pharmaceutical segments [5][6]. - Companies such as Jindike and Hualan Biologicals showed strong performance, while others like Wantai and Zhifei Biologicals lagged behind [6][19]. Investment Recommendations - The report suggests that the vaccine industry is currently under pressure, with a need for companies to focus on innovation and international expansion. It recommends monitoring companies with high technical barriers and differentiated pipelines [8][9][27]. - Specific companies to watch include CanSino for its innovative capabilities and Kanghua Biologicals for its stable demand products [9][27].

Core Insights - The flu activity in southern China is on the rise, with experts predicting an earlier flu season this year compared to previous years [1] - The market for flu vaccines is currently dominated by quadrivalent vaccines, while trivalent vaccines are nearly absent from the self-paid market, leading to a price war among vaccine providers [1][5] Vaccine Availability and Pricing - In Chengdu, several community health centers offer quadrivalent vaccines at a price of 118 yuan per dose, while a specific quadrivalent vaccine from Zhonghui Biological is priced at 349 yuan per dose [2] - The production strategy of vaccine manufacturers has shifted towards quadrivalent vaccines due to higher profit margins, resulting in a significant decrease in the availability of trivalent vaccines in the self-paid market [5][6] Market Dynamics - In 2023, the total number of flu vaccine batches approved for release was 288, with quadrivalent vaccines accounting for 163 batches and trivalent vaccines for 101 batches [7] - The quadrivalent vaccine has become the dominant product in the flu vaccine market, reflecting a trend of increasing consumer preference for vaccines perceived to offer better protection [8] Price Trends - The price of quadrivalent vaccines has dropped significantly, with some prices falling from three-digit to two-digit figures, impacting the profit margins of vaccine manufacturers [10] - For instance, the price of a trivalent vaccine was recorded at 5.5 yuan per dose, marking a new low in the public flu vaccine market [9] Industry Challenges - The flu vaccine market faces challenges such as low vaccination rates and fluctuations in demand, which can lead to "big years" and "small years" in terms of vaccine uptake [11] - The current flu strains circulating, particularly the H3N2 strain, may lead to lower immunity levels in the population, emphasizing the importance of vaccination [12]

Core Insights - The blood products sector has experienced a significant decline in profitability, with a year-on-year net profit decrease of 23.14% in the first three quarters of 2025, and a more severe drop of 30.89% in Q3 [1][2] - The average stock price of the blood products sector has fallen by 8.35% since the beginning of 2025, influenced by short-term performance pressures and market sentiment changes [1][2] Revenue and Profit Trends - In the first three quarters of 2025, the revenue growth rate for the blood products sector was only 0.30%, with Q3 showing a slight improvement at 4.11% [2] - The sales gross margin and net profit margin for Q3 2025 were reported at 40.42% (down 7.26 percentage points year-on-year) and 18.74% (down 10.17 percentage points year-on-year), indicating significant margin compression [2] Valuation Metrics - As of November 10, 2025, the price-to-earnings (P/E) ratio for the blood products sector stood at 30.07, with historical percentiles indicating a rising trend in valuation since 2020 [3] Strategic Focus Areas - Companies in the blood products sector should prioritize upstream plasma station resources and integration capabilities, as these are critical competitive advantages [4] - There is a shift towards upgrading product structures, with a focus on increasing the proportion of high-margin products like coagulation factors and developing new products such as recombinant products and subcutaneous immunoglobulin [4][5] Future Considerations - Attention should be given to potential price changes in blood products over the coming months, as well as advancements in new technologies for producing recombinant human serum albumin [5]

Market Overview - The A-share market experienced fluctuations with the Shanghai Composite Index falling by 0.07% to 4000.14 points, the Shenzhen Component Index down by 0.36%, and the ChiNext Index decreasing by 0.39%. The total trading volume in the A-share market was 1.96 trillion RMB, with over 3500 stocks declining. The household appliances, comprehensive, and textile and apparel sectors led the gains, while the electric equipment, machinery, and computer sectors lagged behind [2][8] - In the Hong Kong market, the Hang Seng Index rose by 0.85% and the Hang Seng Technology Index increased by 0.16%. In overseas markets, the Dow Jones rose by 0.68%, the S&P 500 increased by 0.06%, while the Nasdaq fell by 0.26% [2][8] Important News - The Shanghai Stock Exchange International Investor Conference opened on November 12, 2025, focusing on "Value Leadership and Open Empowerment - New Opportunities for International Capital Investment and M&A." The event attracted over 400 representatives from more than 100 well-known investment institutions across Europe, America, Asia-Pacific, and the Middle East. Discussions centered on new opportunities for investment and M&A in China, driven by macroeconomic stability and policy optimization [3][9] Blood Products Sector - The blood products sector has faced profit pressure, with a year-to-date average stock price decline of 8.35%. The sector's revenue growth for the first three quarters of 2025 was 0.30% year-on-year, with a Q3 growth of 4.11%. However, the net profit attributable to shareholders saw a significant decline of 23.14% year-on-year, with Q3 showing a decrease of 30.89% [10][13] - The sales gross margin and net profit margin for Q3 2025 were 40.42% (down 7.26 percentage points year-on-year) and 18.74% (down 10.17 percentage points year-on-year), respectively. The sector's valuation as of November 10, 2025, had a price-to-earnings ratio (TTM) of 30.07, indicating a high percentile ranking since 2020 [13][14] Lithium Battery Sector - The lithium battery sector showed stable demand in the first three quarters of 2025, with overall revenue reaching 636.19 billion RMB, a year-on-year increase of 16.12%, and a net profit of 62.62 billion RMB, up 40.37% year-on-year. Q3 alone saw revenue of 235.43 billion RMB, a 20.42% increase year-on-year, and a net profit of 25.34 billion RMB, up 58.20% year-on-year [14][15] - The battery segment achieved revenue of 417.27 billion RMB in the first three quarters, with a year-on-year growth of 11.92%. In Q3, revenue reached 154.04 billion RMB, reflecting a 16.63% increase year-on-year [16][15] Traditional Chinese Medicine Sector - The traditional Chinese medicine sector faced ongoing performance pressure in Q3 2025, with an overall revenue decline of 1.57% year-on-year and a net profit decrease of 5.25% year-on-year. The sector's sales gross margin was 40.40%, with a net profit margin of 9.21% [20][23] - Among 69 listed companies in the sector, 49 saw stock price increases year-to-date, with notable performers including Wanbangde and Tianmu Pharmaceutical, which both exceeded 100% growth [23][24]

证券日报网讯华兰生物11月11日在互动平台回答投资者提问时表示，二级市场股价受宏观经济环境、市 场形势、行业发展、投资者价值判断等多方面因素影响，公司高度重视市值管理，以提升上市公司质量 为重点，持续通过完善的公司治理、高效的经营管理、持续稳定的现金分红，不断提高公司市值管理能 力及综合竞争实力，为广大投资者创造可持续的长期回报。 （文章来源：证券日报） ...

Core Viewpoint - The company emphasizes its stable cash flow and commitment to shareholder dividends, aiming to enhance long-term investment value and investor satisfaction [2] Financial Performance - For the period of January to September 2025, the company's operating revenue was 3.379 billion yuan, a decrease of 3.2% compared to the same period last year [2] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 742 million yuan, down 9.17% year-on-year [2] - The decline in revenue and net profit is primarily attributed to the postponement of vaccine sales by the company's subsidiary, with expectations of improved performance in the fourth quarter due to increased sales of flu vaccines [2]